Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Johnson and Johnson
Mallinckrodt
McKinsey
Moodys

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR FELODIPINE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Felodipine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00348686 ↗ Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP) Completed AstraZeneca Phase 4 2006-06-01 The purpose of this study is to investigate effect of candesartan based therapy on percent change of B type natriuretic peptides(BNP) level in the subjects with hypertension and left ventricular hypertrophy.
NCT00367939 ↗ Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine Completed Novartis Phase 3 2005-12-01 The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with ACE inhibitor plus calcium channel blocker
NCT00392262 ↗ A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients Completed Novartis Phase 3 2006-08-01 The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with amlodipine or felodipine alone.
NCT00507845 ↗ Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina Completed Sanofi Phase 4 2007-06-01 Primary: - To assess effectiveness of Ramipril-Felodipine in hypertensive Argentinean patients Secondary: - To assess tolerability of Ramipril-Felodipine in hypertensive Argentinean patients.
NCT00742066 ↗ Role of AT1-receptor Blockers in Insulin-induced Vasodilation. Unknown status Maastricht University Medical Center N/A 2008-03-01 In this study we hypothesize that blocking the angiotensin II AT1-receptor improves the insulin-induced microvascular dilatation. Objectives: 1. Does blockade of the angiotensin II AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients. 2. Does blockade of the angiotensin II AT1-receptor impair the insulin-induced microvascular effects in normotensive control subjects?
NCT00841880 ↗ China Medical University Hospital (CMUH) Triapin Listing Completed Sanofi Phase 4 2009-01-01 The objective of this study is to compare the reduction in office seated systolic blood pressure (BP) following a 8 weeks regimen of ramipril 5mg plus felodipine 5mg versus ramipril 10mg. To compare the response rate (defined as office systolic blood pressure (SBP) / Diastolic blood pressure (DBP) reduce more than 10mmHg from baseline), and BP controlled rate (defined as SBP<140mmHg and/or DBP<90mmHg) and as SBP < 130 mmHg and /or DBP < 80 mmHg in diabetes,chronic kidney disease, known Coronary Arterial Disease (CAD) or CAD equivalent, or 10-year Framingham risk score > 10%. To ascertain the safety and tolerability of ramipril/felodipine versus ramipril in Taiwanese population. To compare compliance with fixed dose combination of ramipril/felodipine versus ramipril treatment.
NCT00905333 ↗ Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal Completed Clínica São Lucas, Hospital Sírio Libanês de Itatiba S/C Phase 1 2008-10-01 The purpose of this study is to evaluate the pharmacokinetic interaction of test formulations of candesartan and felodipine in a combination package comparing with the fasting intake of commercial formulations of both Atacand ® and Splendil®
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Felodipine

Condition Name

Condition Name for Felodipine
Intervention Trials
Hypertension 11
Healthy 5
Left Ventricular Hypertrophy 1
Microcirculation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Felodipine
Intervention Trials
Hypertension 11
Malnutrition 2
Insulin Resistance 1
Hypertrophy, Left Ventricular 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Felodipine

Trials by Country

Trials by Country for Felodipine
Location Trials
China 3
Brazil 2
India 2
Germany 2
Argentina 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Felodipine

Clinical Trial Phase

Clinical Trial Phase for Felodipine
Clinical Trial Phase Trials
Phase 4 7
Phase 3 2
Phase 1 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Felodipine
Clinical Trial Phase Trials
Completed 15
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Felodipine

Sponsor Name

Sponsor Name for Felodipine
Sponsor Trials
AstraZeneca 3
Novartis 2
Sanofi 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Felodipine
Sponsor Trials
Other 14
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Medtronic
Johnson and Johnson
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.